- Home
- RDN vs RARE Comparison
RDN vs RARE Comparison
Compare RDN & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDN
- RARE
- Stock Information
- Founded
- RDN 1977
- RARE 2010
- Country
- RDN United States
- RARE United States
- Employees
- RDN 1000
- RARE N/A
- Industry
- RDN Property-Casualty Insurers
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- RDN Finance
- RARE Health Care
- Exchange
- RDN Nasdaq
- RARE Nasdaq
- Market Cap
- RDN 4.5B
- RARE 3.9B
- IPO Year
- RDN 1992
- RARE 2014
- Fundamental
- Price
- RDN $31.09
- RARE $39.25
- Analyst Decision
- RDN Buy
- RARE Strong Buy
- Analyst Count
- RDN 5
- RARE 14
- Target Price
- RDN $36.80
- RARE $93.50
- AVG Volume (30 Days)
- RDN 1.5M
- RARE 794.2K
- Earning Date
- RDN 04-30-2025
- RARE 05-01-2025
- Dividend Yield
- RDN 3.27%
- RARE N/A
- EPS Growth
- RDN 3.98
- RARE N/A
- EPS
- RDN 3.92
- RARE N/A
- Revenue
- RDN $1,290,283,000.00
- RARE $560,230,000.00
- Revenue This Year
- RDN N/A
- RARE $19.15
- Revenue Next Year
- RDN $3.09
- RARE $32.11
- P/E Ratio
- RDN $7.88
- RARE N/A
- Revenue Growth
- RDN 4.01
- RARE 29.01
- 52 Week Low
- RDN $29.17
- RARE $37.02
- 52 Week High
- RDN $37.86
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- RDN 36.08
- RARE 41.14
- Support Level
- RDN $30.51
- RARE $37.10
- Resistance Level
- RDN $32.72
- RARE $41.37
- Average True Range (ATR)
- RDN 0.75
- RARE 1.76
- MACD
- RDN -0.15
- RARE -0.24
- Stochastic Oscillator
- RDN 18.53
- RARE 33.39
About RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one business segment Mortgage Insurance. The Mortgage Insurance segment aggregates, manages, and distributes U.S. mortgage credit risk for the benefit of mortgage lending institutions and mortgage credit investors, through private mortgage insurance on residential first-lien mortgage loans, and also offers other credit risk management solutions, including contract underwriting, to customers. It also provides other mortgage and real estate products and services through Mortgage Conduit, Title, Real Estate Services, and Real Estate Technology businesses.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.